of these defects is loss of function of the tumour-suppressor gene p53 (Lane. 1992; Vogelstein and Kinzler. 1992) . Although different mechanisms can result in loss of function of p53. allelic loss and mutation of the other gene is most often found (Baker et al.. 1989 : Levine et al.. 1991 : Vogelstein and Kinzler. 1992 . These point mutations are associated with p53 overexpression caused by the decreased breakdown of the tetrameric form with mutant components (Levine et al.. 1991) . The normal level of nuclear p53 expression is extremely low. but the aberrant accumulation of p53 in the tumour cell is detectable with p53-specific antibodies (Remvikos et al.. 1990 : Bartek et al.. 1991 : Lane. 1992 ). In colorectal cancer p53 is overexpressed in 50-70% of tumours (Cunningham et al.. 1992 : Sun et al.. 1992 ; reviewed by Harris and Hollstein. 1993) .
Because mutation in the p53 gene and the consequent overexpression of p53 are associated with tumour tissue. both. wrild-type and mutant p53 may act as targets of tumour-specific humoral and cellular immune responses. p53-specific antibodies in the sera of patients have been studied in breast cancer (Crawford et al.. 1982; Davidoff et al.. 1992 . Schlichtholz et al.. 1992 : Mudenda et al.. 1994 . in lung cancer (Winter et al.. 1992 : Schlichtholz et al.. 1994 . in B-cell lymphoma (Caron de Fromentel et al.. 1987 ) and more recently in various other types of cancer (Labrecque et al., 1993 : Lubin et al.. 1993 : Angelopoulou et al.. 1994 . In breast cancer. a p53 antibody response was found to be an indicator of poor prognosis (Schlichtholz et al.. 1992 : Mudenda et al.. 1994 .
Using an ELISA. we tested the serum samples taken preoperatively from 255 patients that participated in the CRAB clinical trial on the relationship between blood transfusion and colorectal cancer prognosis (Houbiers et al.. 1994 (Mfiller et al. 1994) .
The ELISA absorption data of our study were correlated with the manufacturer's control sera ('low' or The absorption results of sera from our own serum bank. added to control intertest variation showed good concordance between the different assays. Additionally, testing of the 'medium' control serum that was provided by the manufacturer resulted in p53-TIs in the narrow range from 310% to 350% in all assays. The sera of two patients that were excluded from the CRAB study because of a benign colon tumour had a p53-TI of < 10%. The sera of 40 
Results
Of the 255 tested preoperative sera from patients with colorectal cancer, 70.2% had a p53-antibody titre index (p53-TI) that was higher than the manufacturers 'low' control serum (i.e. >0%. Table I ). When results of p53-TI < 10% were regarded as absence of p53 antibodies. 25.5% of the sera were positive (Table I ). The cut-off level of 10% was not arbitrarily chosen; samples with a lower absorption than the 'low control' that was provided by the manufacturer had a p53-TI between -10% and 0%. Furthermore, the relevance of the I0% cut-off level was confirmed by the results of ten sera that were tested in an unmarked order for p53 antibodies using immunoblotting with recombinant p53 (Western blotting). The six sera that had a p53-TI < 10% were negative by Western blotting (Figure 1) Follow-up and p53 antibodies Colorectal cancer prognosis was expressed in terms of overall survival, disease-free survival and disease-free period at 3 years of follow-up and was analysed on the basis of Kaplan-Meier curves as previously reported (Houbiers et al.. 1994) . Associations between cancer prognosis and p53 antibodies were observed (Table III) 
Disaussion
Using ELISA, we studied the presence of p53 antibodies in preoperatively collected serum of 255 patients with colorectal cancer. A total of 70.2% of the patients had reactivity above the 'low' control (Table I) ; when employing a cut-off of p53-TI < 10%, 25.5% of the patients were positive for p53 antibodies. The cut-off level of 10% was not arbitrarily chosen; sera with ELISA results below the 'low control' ranged from p53-TI -10% to 0% and the six sera with p53-TI < 10% that additionally were tested with immunoblotting were negative for p53 antibodies.
The only study reporting on p53 antibodies in colorectal cancer patients used different assays and detected a positive antibody status in 13 patients (16%) out of 82 tested (Angelopoulou et al., 1994) . That report, however, gives no clinical or pathological details on the patient group, nor does it correlate the results with prognosis.
The observed associations between p53 antibody positivity 640 and factors related to poor prognosis of colorectal cancer suggest that intracellular p53 accumulation is not sufficient to elicit a humoral response, but that free p53 has to be presented to the immune system. Thus, p53 antibodies seem an expression of aggressive and extended tumours. We found that low differentiation grade, flat or circular tumour shape, tumour invasion into blood vessels, and lymph node metastases were associated with p53 antibodies. antibodies (Davidoff et al., 1992; Winter et al., 1992; Lubin et al., 1993) . The origin of detectable p53 antibodies in serum from one patient with a primary tumour lacking p53 overexpression is unclear. This autoantibody induction may be due to the unusual presentation of large amounts of wild-type p53 from necrotic large tumours or metastases. It is also conceivable that the p53 gene is mutated and p53 -although the altered protein does not accumulate and thus is undetectable by immunohistochemistry -is presented to the immune system (T-helper cells) differently or in higher concentrations resulting in antibody induction.
Although mutations throughout the p53 gene can result in stabilisation and overexpression, the study by Davidoff et al. (1992) found that only tumours with complexes between p53 and a 70 kDa heat shock protein can elicit p53 antibodies. These complexes were primarily found in tumours with p53 mutations in exons 5 and 6, whereas tumours of patients without p53 antibodies exclusively displayed mutations in exons 7 and 8. This finding gives an explanation for the low frequency of p53 antibodies in patients with p53 overexpressing tumours.
The induction of p53 antibodies is an autoimmunisation process caused by the presentation of accumulated p53 to the immune system (Lubin et al.. 1993 
